Latest News

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

The FDA approved a single-use autoinjector for lerodalcibep-liga alongside an updated lerodalcibep-liga indication reflecting MACE risk reduction from LDL-C lowering with statins or add-on PCSK9 inhibitors.

Pooled 2-year BE HEARD EXT data show shorter disease duration was linked with higher stringent response rates to bimekizumab in HS.

Dana Rizk, MD, joins hosts Brendon Neuen and Shikha Wadhwani to unpack 2-year VISIONARY data showing sibeprenlimab stabilizes eGFR in IgAN.

Ronald D'Agostino, DO, discusses the 2026 HFpEF pathway, H2FPEF screening, and comorbidity-first heart failure care.

Lieberman discusses atypical anaphylaxis signs in infants and toddlers and why epinephrine remains underused.

One year after brensocatib's FDA approval, 2 pulmonologists describe real-world response and a new CHEST guideline.

Tiffany Mayo, MD, discusses the pressure of representation in medical leadership, setting boundaries, and staying authentic as a woman of color.

Rima Rachid, MD, discusses the purified MTT formulation, phase 2 trial design, and the gut bacteria driving protection against peanut allergy.

New research links germline genetic variants to CAR T cell toxicity risk and expansion in lymphoma patients treated with axi-cel.

Recent phase 2a findings on PORT-77 show rapid, dose-dependent plasma PPIX reductions in erythropoietic protoporphyria and X-linked protoporphyria.

Experts discussed FCS diagnostic scoring tools, diagnostic delays, and new data on olezarsen and plozasiran for lowering triglycerides in a recent clinical forum.

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

In this discussion, Eichenfield discusses which advances in eczema he sees as most impactful and where unmet needs remain for pediatric patients.

The bispecific TSLP/IL-13 inhibitor BEL512 met its primary endpoint and all secondary endpoints in adults with chronic rhinosinusitis with nasal polyps.

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

This Q&A highlights recent data and FDA approvals described in the pediatric atopic dermatitis space by Lawrence Eichenfield, MD.

A pair of clinical forums examined new CKM staging, SGLT2 and MRA trial data, and the barriers delaying heart failure treatment.

Sonelokimab hit its primary ACR50 end point and all key secondary end points in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.

Once-weekly insulin icodec hits US pharmacies, simplifying basal dosing for type 2 diabetes with new titration rules and promising A1c results.

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

The FDA accepted EIT Pharma’s lonafarnib NDA for chronic hepatitis D, supported primarily by the phase 3 D-LIVR trial.